Arcus Biosciences Cash on Hand 2017-2022 | RCUS

Arcus Biosciences cash on hand from 2017 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Arcus Biosciences Annual Cash on Hand
(Millions of US $)
2021 $499
2020 $729
2019 $188
2018 $257
2017 $176
2016 $
Arcus Biosciences Quarterly Cash on Hand
(Millions of US $)
2022-03-31 $1,214
2021-12-31 $499
2021-09-30 $525
2021-06-30 $721
2021-03-31 $827
2020-12-31 $729
2020-09-30 $782
2020-06-30 $462
2020-03-31 $158
2019-12-31 $188
2019-09-30 $191
2019-06-30 $224
2019-03-31 $242
2018-12-31 $257
2018-09-30 $258
2018-06-30 $266
2018-03-31 $280
2017-12-31 $176
2017-09-30
2017-06-30
2017-03-31
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.357B $0.383B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00